Jounce Therapeutics, Inc. (NASDAQ:JNCE) traded at $10.95 at last check on Tuesday, Sep 15, making an upward move of 23.73% on its previous day’s price.

Looking at the stock we see that its previous close was $8.85 and the beta (5Y monthly) reads 1.66 with the day’s price range being $8.91 – 11.72. The company has a 12-month trailing PE ratio of 17.78. In terms of its 52-week price range, JNCE has a high of $10 and a low of $2.79. The company’s stock has gained about 133.97% over that past 30 days.

Jounce has a market cap of $356.64 Million and is expected to release its quarterly earnings report on August 07, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the JNCE stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.71, with the EPS growth for the year declined at -$2.42 for 2020 and -$2.79 for next year. These figures represent -2.46% and at 0.15% growth in EPS for the two years respectively.

On the other hand, looking at the outlook for the JNCE stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of 50% Buy.

Based on estimates by 6 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 2 have rated the Jounce Therapeutics, Inc. (JNCE) stock as a Hold, while 2 rate it as a Buy. 1 analysts rate it as outperform while none of them rated it as underperform, whereas 1 suggests the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the JNCE stock currently stands at 0, and the current price level is 78.6% off its SMA20 and 97.19% from its 50-day simple moving average. The RSI (14) is pointing at 83.23 while the volatility over the past week is 13.42% and drops to 11.11% over the past one month. The beta value is 1.66, while the average true range (ATR) is currently pointing at 0.85. The average price target for the stock over the next 12 months is $10.88, with the estimates having a low of $5.5 and a high of $15. These price ends are -49.77% and +36.99% off the current price level respectively, although investors could be excited at the prospect of a +5.02% if the JNCE share price touches on the median price of $11.5.

Let’s briefly compare Jounce (JNCE) stock to its peers. We find that today’s price change of +23.73% and +218.31% over the past 12 months for JNCE betters that of Zoetis Inc Cl A (ZTS), which has seen its stock price rise 0.88% in the latest trading session and is +35.64% over the last one year. Another of its peers Takeda Pharmaceutical Co. Ltd (TAK) has climbed 0.27% today, and is +6.29% up over the past year, while Catalent Inc (CTLT) is also up 23.73% yet its price remains in the green at 218.31% over the same period. Zoetis has a P/E ratio of 48 compared to Jounce’s 17.78 and Takeda’s 22.7. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.52% and 0.01%, respectively, in early deals.

Coming back to Jounce Therapeutics, Inc. (NASDAQ:JNCE), we note that the average 3-month trading volume was 1.01 Million, while that of the preceding 10-day period stands at 867.22 Million. Current shares outstanding are 34.21 Million.

According to data from Thomson Reuters, insiders hold 12.88% of the company’s shares while institutions hold 74.64%. The data shows that short shares as of August 30, 2020, stood at 2.14 Million at a short ratio of 13.51. This represents a 6.25% Short interest in Shares outstanding on August 30, 2020. Shares short dropped in August from the previous month at 2.23 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock +25.43% up in year-to-date price movement.